VA-CTA
2.4.2018 23:42:12 CEST | Business Wire | Press release
The Consumer Technology Association (CTA) today announced that CES Asia 2018 will highlight advancements in artificial intelligence (AI) as a new dedicated product category on the show floor, building on the successful demonstration of AI applications across the latest consumer tech products showcased at CES earlier this year.
Alibaba A.I. Labs, Baidu DuerOS and iFLYTEK, among others, will exhibit the latest in big data analytics, speech recognition and predictive technology. With China setting the pace to become a global innovation leader in AI, CES Asia will bring together the biggest players shaping the future of artificial intelligence.
“Artificial intelligence is one of those exciting technologies that will become ubiquitous in the next decade as it becomes more deeply embedded in the products that we use day in and day out to make our lives better, ” said John T. Kelley, senior director, international programs and show director, CES Asia. “AI is already being incorporated in everyday consumer technology products that provide practical benefits, including cars, smart homes, robotics, health and wellness devices and home security. China is leading the way in AI, embracing innovation and setting global standards and it will be front and center during CES Asia 2018!”
More, ARM Accelerator and the Hong Kong University of Science and Technology will bring several cutting-edge companies to CES Asia. IFLYTEK, who is currently valued at $6.3 billion USD, will return to the show floor as one of China’s most innovative tech companies. Cutting edge innovation in AI is also emerging from other Asian Countries. GT Robot Technology, a Singapore-based firm that specializes in humanoid robotic solutions, will exhibit at CES Asia for the first time.
“GT Wonder Boy is Singapore’s first SMART social bot companion, a reflection of Singapore’s shift towards a SMART Nation,” said Revathi, a spokesperson of GT Robot Technology Pte Ltd. “We are harnessing the power of technology in an era of digitisation, driving efficiency, creating something truly transformational.”
Other notable companies exhibiting include: Camsing Global, EMOS Technologies, Hangzhou Taruo Information Technology, HUMU Augmented Audio Cushion, Moran, Morpx, Sogou Teemo and Xvisio Technology.
Owned and produced by International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex, CES Asia 2018 will run from June 13-15, in Shanghai, China. The premier event for the consumer technology industry in Asia, CES Asia showcases major brands and innovative companies across several vertical markets in the Asian marketplace.
Visit CESAsia.com for the latest show news, information, photos, b-roll and more.
Note to Editors:
High-definition video b-roll from CES Asia 2017 is available for easy download on CESAsia.com . Journalists traveling from outside of China will require a J-1 or J-2 visa . For questions about exhibiting at CES Asia, contact Brian Moon at bmoon@CTA.tech or +1 703-907-4351.
About CES Asia:
Owned and produced by the International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this new event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers, international media and a limited number of consumers from China. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.
About International CES (Shanghai) Exhibition Co. Ltd. and CTA:
International CES (Shanghai) Exhibition Co. Ltd. is a wholly foreign-owned enterprise by the Consumer Technology Association (CTA), a trade association representing the $321 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About Shanghai Intex:
Shanghai Intex Exhibition Co., Ltd was originally the exhibition organizing business of Shanghai Intex, a pioneering exhibition organizer established in 1995. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibition Investment (Dubai) Limited. Starting in 1998, Shanghai Intex has organized over 100 trade shows and conferences with a sum total exhibition space in excess of 2 million sqm. Shanghai Intex is comprised of professional teams with a wealth of experience in organizing major international events, covering the creative industry, healthcare, lifestyle, advanced manufacturing and consumer electronics.
UPCOMING EVENTS
-
CES on the Hill
April 16, Washington, DC -
Digital Patriots Dinner
April 17, Washington, DC -
CES Asia 2018 –
Register
June 13-15, Shanghai, China -
CEO Summit
June 24-27, Barcelona, Spain -
CES Unveiled Amsterdam
September 27, Amsterdam, Netherlands -
CES 2019
January 8-11, Las Vegas, NV
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005890/en/
Contact:
Consumer Technology Association
Teresa Hsu, 703-907-5259
thsu@CTA.tech
www.CESAsia.com
or
Bernice
Morquette, 703-907-7651
bmorquette@CTA.tech
www.CES.tech
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
